The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Nearly one in five women worldwide are now living with obesity
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
